{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:30:31Z","timestamp":1758040231608,"version":"3.44.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.amjcard.2022.11.006","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T04:25:15Z","timestamp":1670214315000},"page":"68-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Association of Neurohormonal Antagonists on Incident Cardiotoxicity in Patients With Breast Cancer"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-4704","authenticated-orcid":false,"given":"Goyal","family":"Umadat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Cornell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilip","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Michael","family":"Gharacholou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2022.11.006_bib0001","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study","volume":"13","author":"Patnaik","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0002","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0003","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0004","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12609-017-0249-4","article-title":"Incidence, diagnosis, and treatment of cardiac toxicity from trastuzumab in patients with breast cancer","volume":"9","author":"Nowsheen","year":"2017","journal-title":"Curr Breast Cancer Rep"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaoncol.2015.3709","article-title":"Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer","volume":"2","author":"Dang","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0006","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"Romond","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0007","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","article-title":"Long-term cardiac safety analysis of NCCTG N9831 (alliance) adjuvant trastuzumab trial","volume":"34","author":"Advani","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0008","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"Herceptin Adjuvant (HERA) Trial Study Team. 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0009","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","article-title":"Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)","volume":"32","author":"de Azambuja","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0010","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0011","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2\u00a0\u00d7\u00a02 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0012","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-Receptor inhibition with candesartan to prevent Trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0013","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0014","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0015","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0016","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1001\/jamaoncol.2021.3395","article-title":"Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: a randomized clinical trial","volume":"7","author":"Livi","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0017","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0018","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of Lisinopril versus Carvedilol to prevent Trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0019","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0021","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021931","article-title":"Development and validation of a risk score model for predicting the cardiovascular outcomes after breast cancer therapy: the CHEMO-RADIAT score","volume":"10","author":"Kim","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0022","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: cardio-oncology","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0023","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0024","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0025","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0026","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jgo.2017.04.001","article-title":"Cardio-oncology in the older adult","volume":"8","author":"Reddy","year":"2017","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0027","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0028","first-page":"2175","article-title":"Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer","volume":"22","author":"Nicolazzi","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0029","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ehf2.12695","article-title":"Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial","volume":"7","author":"Meessen","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.amjcard.2022.11.006_bib0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","article-title":"The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Omland","year":"2022","journal-title":"JACC CardioOncol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914922011973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914922011973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:44:35Z","timestamp":1757573075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914922011973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":30,"alternative-id":["S0002914922011973"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2022.11.006","relation":{},"ISSN":["0002-9149"],"issn-type":[{"type":"print","value":"0002-9149"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Neurohormonal Antagonists on Incident Cardiotoxicity in Patients With Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2022.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}